Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

Nearly two years after FDA issued a final rule requiring radiologists to tell women whether their breasts are “dense” or “not dense” after a mammogram, the notification has become nearly universal.

October 02, 2026

Vol.52 No.36

By Claire Marie Porter

Cancer Policy

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

In Brief

ARPA-H launches SURPASS program to accelerate clinical trials

ARPA-H launched the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, together with three complementary projects, aimed at removing barriers that slow clinical development and help promising treatments reach patients sooner.

October 02, 2026

Vol.52 No.36

Drugs & Targets

FDA accepts NDA and grants Priority Review to Lynkuet for vasomotor symptoms due to endocrine therapy in breast cancer

FDA accepted the company’s supplemental New Drug Application and granted Priority Review designation for Lynkuet (elinzanetant) under investigation for the treatment of moderate to severe vasomotor symptoms (also known as hot flashes) in women receiving endocrine therapy for treatment of breast cancer.

October 02, 2026

Vol.52 No.36

How biology is reshaping breast cancer care

Breast cancer treatment has changed dramatically over the past decade. One of the most important advances has been our growing ability to understand the biology of each patient’s cancer and use those insights to guide treatment decisions more precisely. That shift is helping make personalized cancer care a reality.

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

FDA accepts NDA and grants Priority Review to Lynkuet for vasomotor symptoms due to endocrine therapy in breast cancer

How biology is reshaping breast cancer care

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

Two years after FDA’s breast density notification rule, there is still no standard for follow-upSo far, 38 million patients have received a dense breast notification. Now what?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

FDA accepts NDA and grants Priority Review to Lynkuet for vasomotor symptoms due to endocrine therapy in breast cancer

How biology is reshaping breast cancer care

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Never miss an issue!

Login

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?